Möller Jens Carsten, Körner Yvonne, Cassel Werner, Meindorfner Charlotte, Krüger Hans-Peter, Oertel Wolfgang H, Stiasny-Kolster Karin
Department of Neurology, Philipps-University, 35033 Marburg, Germany.
Sleep Med. 2006 Jun;7(4):333-9. doi: 10.1016/j.sleep.2005.08.009. Epub 2006 Mar 22.
Sudden onset of sleep (SOS) was recently reported in patients with Parkinson's disease (PD) under dopaminergic treatment. Here, we investigated as to what extent SOS is found in patients with restless legs syndrome (RLS), who are frequently treated with dopaminergic drugs, and controls.
A questionnaire survey on SOS was administered to 156 RLS patients and 126 controls.
While no significant difference between RLS patients and controls was detected in Epworth sleepiness scale (ESS) scores (P=0.76), the prevalence of SOS was higher in RLS patients (32.7%) than in controls (19.8%) (P=0.02). Significant predictors of SOS in RLS were ESS score (odds ratio (OR) 16.4), male sex (OR 4.6), duration of night-time sleep (OR 3.0), and age (OR 2.9), while no association was observed for duration or severity of the disease. Patients on dopaminergic therapy usually featured a lower risk of SOS than untreated patients. Falling asleep while driving was reported by 14.6% of all RLS patients with a driver's license and associated with increased risk of accident (OR 7.1).
RLS patients who are untreated, male, and elderly should be assessed for the presence of SOS. In contrast to PD, dopaminergic drugs may reduce the risk of SOS in RLS. The possible benefit of the drugs should be investigated particularly in male patients.
帕金森病(PD)患者在接受多巴胺能治疗时,近期有突然入睡(SOS)的报道。在此,我们调查了不宁腿综合征(RLS)患者(常接受多巴胺能药物治疗)及对照组中SOS的发生率。
对156例RLS患者和126例对照者进行了关于SOS的问卷调查。
虽然RLS患者与对照组在爱泼沃斯思睡量表(ESS)评分上无显著差异(P = 0.76),但RLS患者中SOS的发生率(32.7%)高于对照组(19.8%)(P = 0.02)。RLS患者中SOS的显著预测因素为ESS评分(优势比(OR)16.4)、男性(OR 4.6)、夜间睡眠时间(OR 3.0)和年龄(OR 2.9),而未观察到疾病持续时间或严重程度与SOS有关。接受多巴胺能治疗的患者发生SOS的风险通常低于未治疗患者。所有有驾照的RLS患者中有14.6%报告在驾驶时入睡,且这与事故风险增加相关(OR 7.1)。
未治疗的、男性及老年RLS患者应评估是否存在SOS。与PD不同,多巴胺能药物可能降低RLS患者发生SOS的风险。应特别在男性患者中研究这些药物可能带来的益处。